| Literature DB >> 33773610 |
Messoud Ashina1, Gisela M Terwindt2, Mohammad Al-Mahdi Al-Karagholi3, Irene de Boer2, Mi Ji Lee4, Debbie L Hay5, Laura H Schulte6, Nouchine Hadjikhani7, Alexandra J Sinclair8, Håkan Ashina3, Todd J Schwedt9, Peter J Goadsby10.
Abstract
Migraine is a disabling neurological disorder, diagnosis of which is based on clinical criteria. A shortcoming of these criteria is that they do not fully capture the heterogeneity of migraine, including the underlying genetic and neurobiological factors. This complexity has generated momentum for biomarker research to improve disease characterisation and identify novel drug targets. In this Series paper, we present the progress that has been made in the search for biomarkers of migraine within genetics, provocation modelling, biochemistry, and neuroimaging research. Additionally, we outline challenges and future directions for each biomarker modality. We also discuss the advances made in combining and integrating data from multiple biomarker modalities. These efforts contribute to developing precision medicine that can be applied to future patients with migraine.Entities:
Year: 2021 PMID: 33773610 DOI: 10.1016/S0140-6736(20)32162-0
Source DB: PubMed Journal: Lancet ISSN: 0140-6736 Impact factor: 79.321